Nuclear Reprogramming Using Exogenous miRNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming differentiated somatic cells to produce induced pluripotent stem cells are inefficient, with low production yields and potential tumorigenesis risks, particularly when using virus vectors and certain reprogramming factors like c-Myc.
Innovation Solution
Introducing specific exogenous miRNAs, such as those from the hsa-miR-302-367 cluster, in conjunction with nuclear reprogramming factors like Oct3/4, Klf4, and Sox2, to enhance the efficiency of somatic cell reprogramming into induced pluripotent stem cells, thereby increasing colony formation and maintaining pluripotency without Sox family members.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If virus vectors are used to introduce reprogramming factors into somatic cells, then reprogramming can be achieved, but the efficiency is low and tumorigenesis risk increases
Solution Approach 1:
The invention changes the chemical composition parameter by replacing viral vectors with non-viral delivery methods (liposomes, electroporation, nucleofection), and modifies the reprogramming factor composition by adding specific miRNAs (miR-302, miR-371-373 clusters) to the traditional transcription factors, thereby improving both efficiency and safety
Solution Approach 2:
The invention creates a composite reprogramming system that combines traditional transcription factors (Oct3/4, Sox2, Klf4, c-Myc) with specific miRNAs (miR-302, miR-371-373 clusters) and delivery vehicles (liposomes, polymers), forming a multi-component system that achieves high efficiency without viral oncogenic risks
2Productivity
If c-Myc is included in the reprogramming factors, then reprogramming efficiency improves, but tumorigenesis risk increases
Solution Approach 1:
The invention extracts c-Myc from the essential reprogramming factor combination and replaces it with alternative factors (Klf4, Nanog, Lin28) combined with specific miRNA clusters, thereby maintaining reprogramming efficiency while eliminating the tumorigenesis risk associated with c-Myc
Solution Approach 2:
The invention changes the molecular composition parameter by substituting c-Myc with a combination of alternative transcription factors and specific miRNAs (miR-302, miR-371-373 clusters) that can drive reprogramming without oncogenic side effects
3Reliability
If embryonic stem cells are used for transplantation, then pluripotency is maintained, but rejection and ethical concerns arise
Solution Approach 1:
The invention creates a copy of embryonic stem cell pluripotency by reprogramming adult somatic cells to express embryonic stem cell markers (Oct3/4, Nanog, SSEA-3, SSEA-4) and acquire similar properties, thereby providing an alternative that avoids ethical concerns and rejection issues while maintaining pluripotency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances nuclear reprogramming efficiency, producing at least 1.5 times more induced pluripotent stem cell colonies compared to methods without miRNAs, while reducing tumorigenesis risks and ethical concerns associated with embryonic stem cells.
Implementation Method 1
Small RNAs are known to function as guide molecules to find a target during the process of inhibition of translation, mRNA degradation, or chromatin structural change via the RNA interference (RNAi)/miRNA molecular mechanism
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention relates to a method for preparing an induced pluripotent stem cell from a somatic cell, comprising a step of nuclear reprogramming of the somatic cell with a nuclear reprogramming factor(s) in the presence of at least one miRNA, wherein the miRNA has a capavity to offer a higher nuclear reprogramming efficiency in the presence of the miRNA than in the absence of the miRNA, and wherein the nuclear reprogramming factor comprises at least (a) an Oct family member, (b) an Oct family member and a Klf family member, (c) an Oct family member and Nanog, or (d) an Oct family member, a Klf family member, and an Myc family member, but it does not comprise an Sox family member.